An innovative lyophilization method, known as Active Freeze Drying, is transforming the production of bulk pharmaceutical powders. Developed by Hosokawa Micron, this technology utilizes a single, sterilizable, closed vessel to deliver fine, lump-free powder with significant advantages, including enhanced operator safety, reduced equipment requirements, and a contaminant-free final product. As a result, pharmaceutical manufacturers worldwide are reconsidering their reliance on traditional tray-type freeze-drying methods.
Validation is a critical challenge in pharmaceutical manufacturing, and freeze-drying is no exception. Manufacturers of active pharmaceutical ingredients (APIs) must comply with stringent standards set by regulatory bodies such as the EMA, FDA, cGMP, and GAMP. They must document and demonstrate that their processes consistently yield the expected results. Hosokawa Micron's innovative Active Freeze Drying technology addresses this challenge by producing fully homogeneous batches of sterile material, making validation easier, faster, and more cost-effective.